IONIS-FB-LRx is a Antisense Oligonucleotide owned by F. Hoffmann-La Roche, and is involved in 5 clinical trials, of which 2 were completed, 2 are ongoing, and 1 is planned.
IONIS-FB-LRx acts by inhibiting CFB. A complement system is a group of proteins that trigger or initiate the inflammatory response. IONIS-FB-LRx by inhibiting complement factor b reduces the dry age-related macular degeneration.
The revenue for IONIS-FB-LRx is expected to reach a total of $1.2bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the IONIS-FB-LRx NPV Report.
IONIS-FB-LRx is under development for the treatment of geographic atrophy associated dry age-related macular disease and complement-mediated diseases including primary immunoglobulin A (IgA) nephropathy. It is a ligand conjugated antisense oligonucleotide (LICA) targeting complement factor b. It is administered through subcutaneous route.
F. Hoffmann-La Roche Overview
F. Hoffmann-La Roche (Roche) is a biotechnology company that develops drugs and diagnostics to treat major diseases. It provides medicines for the treatment of cancer, other auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. The company also offers in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management solutions. Roche conducts research to identify novel methods to prevent, diagnose, and treat diseases. The company offers its products and services to hospitals, commercial laboratories, healthcare professionals, researchers, and pharmacists. Together with its subsidiaries and partners, the company has operations in various countries. Roche is headquartered in Basel, Switzerland.
The company reported revenues of (Swiss Francs) CHF62,801 million for the fiscal year ended December 2021 (FY2021), an increase of 7.7% over FY2020. In FY2021, the company’s operating margin was 28.9%, compared to an operating margin of 31.8% in FY2020. In FY2021, the company recorded a net margin of 22.2%, compared to a net margin of 24.5% in FY2020.
Quick View – IONIS-FB-LRx
|Highest Development Stage|